Advertisement

Prognostic Value of HLA in Genitourinary Tumors

  • Arthur I. Sagalowsky
  • Marilyn S. Pollack
Part of the Cancer Treatment and Research book series (CTAR, volume 19)

Abstract

Before one may properly interpret available data on associations of the HLA system with genitourinary tumors, one first must understand the basic structure and function of HLA and the possible mechanisms linking it with disease.

Keywords

Renal Cell Carcinoma Mycosis Fungoides Hairy Cell Leukemia Antigen Frequency Genitourinary Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dausset J, Svejgaard A: Introduction. In: HLA and Disease, Dausset J, Svejgaard A (eds). Copenhagen: Munksgaard, pp 9–10, 1977.Google Scholar
  2. 2.
    Payne R: The HLA complex: Genetics and implications in the immune response. In: HLA and Disease, Dausset J, Svejgaard A (eds). Copenhagen: Munksgaard, pp 20–31, 1977.Google Scholar
  3. 3.
    Dausset J: Les systèmes d’histocompatibilité et la susceptibilité au cancer. Presse Méd 76:1397–1400, 1968.PubMedGoogle Scholar
  4. 4.
    Bodmer WF: Evolutionary significance of the HLA system. Nature 237:139–145, 1972.PubMedCrossRefGoogle Scholar
  5. 5.
    Macurova H, Ivanyi P, Sajdlova H, Trojan J: HLA antigens in aged persons. Tissue Antigens 6:269–271, 1975.PubMedCrossRefGoogle Scholar
  6. 6.
    Bender K, Riiter G, Mayerova A, Hiller C. Studies on the Heterozygosity at the HL-A gene loci in young and old individuals. International Symposium on HL-A Reagents, Ragsmey RH, Sprack JV (eds). Basel: Karger, pp 287–290, 1973.Google Scholar
  7. 7.
    Gerkins VR, Ting A, Menck HT, Casagrande JT, Terasaki PI, Pike MC, Henderson BE: HLA heterozygosity as a genetic marker of long-term survival. J Natl Cancer Inst 52(6):1909–1911, 1974.PubMedGoogle Scholar
  8. 8.
    Schaller JG, Hansen JA: HLA relationships to disease. Hospital Practice 16(5):41–49, 1981.PubMedGoogle Scholar
  9. 9.
    McDevitt HD, Benacerraf B: Genetic control of specific immune responses. Adv Immunol 11:31–74, 1970.CrossRefGoogle Scholar
  10. 10.
    Dausset J: HLA and association with malignancy: a critical review. In: HLA and Malignancy, Murphy GP, Cohen E, Fitzpatrick JE, Pressman D (eds). New York, NY: Alan R Liss Inc, pp 131–144, 1977.Google Scholar
  11. 11.
    Mittal KK: Possible mechanisms for association of HLA antigens and disease. In: HLA and Malignancy, Murphy GP, Cohen E, Fitzpatrick JE, Pressman D (eds). New York, NY: Alan R Liss Inc, pp 39–51, 1977.Google Scholar
  12. 12.
    Lilly F, Boyse EA, Old LJ: Genetic basis of susceptibility to viral leukaemogenesis. Lancet ii:1207–1209, 1964.CrossRefGoogle Scholar
  13. 13.
    Amiel JL: Study of the leukocyte phenotypes in Hodgkin’s disease. Histocompatibility testing. Copenhagen: Munksgaard, p 79, 1967.Google Scholar
  14. 14.
    Simons MJ, Amiel JL: HLA and malignant disease. In: HLA and Disease, Dausset J, Svejgaard A (eds). Copenhagen: Munksgaard, pp 212–232, 1977.Google Scholar
  15. 15.
    Falk J, Osoba D: The HLA system and survival in malignant disease: Hodgkin’s disease and the carcinoma of the breast. In: HLA and Malignancy, Murphy GP (ed). New York: Alan R Liss Inc, pp 205–216, 1977.Google Scholar
  16. 16.
    Lynch HT, Thomas RJ, Terasaki PI, Ting A, Guirgis HA, Kaplan AR, Chaperon E, Magee H, Lynch J, Kraft C: HL-A in cancer ‘Family N’ Cancer 36:1315–1320, 1975.PubMedCrossRefGoogle Scholar
  17. 17.
    Dick HM: HLA and disease: Introductory review. Brit Med Bull 34:271–274, 1978.PubMedGoogle Scholar
  18. 18.
    Thomson G, Bodmer W: The genetic analysis of HLA and disease association. In: HLA and Disease, Dausset J, Svejgaard A (eds). Copenhagen: Munksgaard, pp 84–93, 1977.Google Scholar
  19. 19.
    Cohen E, Singal DP, Khurana K, Gregory SG, Cox C, Sinks L, Henderson E, Fitzpatrick JE, Highby D: HLA-A9 and survival in acute lymphocytic leukemia and myelocytic leukemia. In: HLA and Malignancy, Murphy GP (ed). New York NY: Allan R Liss Inc, pp 65–70, 1977.Google Scholar
  20. 20.
    Svejgaard A, Ryder L: Associations between HLA and disease. In: HLA and Disease, Dausset J, Svejgaard A (eds). Copenhagen: Munksgaard, pp 46–71, 1977.Google Scholar
  21. 21.
    DeWolf WC, Lange PH, Einasson ME, Yunis EJ: HLA and testicular cancer. Nature 277:216–217, 1979.PubMedCrossRefGoogle Scholar
  22. 22.
    Takasugi M, Terasaki PI, Henderson B, Mickey MR, Menck H, Thompson RW: HL-A antigens in solid tumors. Cancer Res 33:648–650, 1973.PubMedGoogle Scholar
  23. 23.
    Valleteau M, Ganansia R, Hors J, Letexier A, Moria M: Cancer du rein familial et système HLA. Nouv Presse Med 3:1539–1542, 1974.Google Scholar
  24. 24.
    Braun WE, Strimlan CV, Negron AG, Straffon RA, Sachary AA, Bartee SL, Grecek DR: The association of W17 with familial renal cell carcinoma. Tissue Antigens 6:101–104, 1975.PubMedCrossRefGoogle Scholar
  25. 25.
    Pilepich MV, Berkman EM, Goodchild NT: HLA typing in familial renal carcinoma. Tissue Antigens 11:487–488, 1978.PubMedCrossRefGoogle Scholar
  26. 26.
    Kuntz BME, Schmidt GD, Scholz S, Albert ED: HLA-antigens and hypernephroma. Tissue Antigens 12:407–408, 1978.PubMedCrossRefGoogle Scholar
  27. 27.
    Terasaki PI, Mickey MR: HL-A haplotypes of 32 diseases. Transplant Rev 22:105–119, 1975.PubMedGoogle Scholar
  28. 28.
    Terasaki PI, Perdue ST, Mickey MR: HLA frequencies in cancer. A second study. In: Genetics of Human Cancer, Mulvihill JJ, Miller RW, Fraumeni JF (eds). New York: Raven Press, pp 321–328, 1977.Google Scholar
  29. 29.
    Majsky A, Abrahamova J, Koutecky J: Wilms’ tumor and HLA antigens. Tissue Antigens 11:74, 1978.Google Scholar
  30. 30.
    Evers KG, Gutjahr P, Zachiedrich S, Haase W, Knoop U: Lack of association between HLA specificities and Wilms’ tumor. Eur J Pediatr 136:47–49, 1981.PubMedCrossRefGoogle Scholar
  31. 31.
    Ryder LP, Andersen E, Svejgaard A (eds): HLA and Disease Registry: Third Report. Copenhagen: Munksgaard, 1979.Google Scholar
  32. 32.
    Majsky A, Abrahamova J, Koutecky J: HLA antigens and neuroblastoma. Tissue Antigens 12:156, 1978.PubMedCrossRefGoogle Scholar
  33. 33.
    Catalona WJ: Commentary on the immunobiology of bladder cancer. J Urol 118:2–6, 1977.PubMedGoogle Scholar
  34. 34.
    Takasugi M, Terasaki PI, Henderson B, Mickey MR, Menck H, Thompson RW: HL-A antigens in solid tumors. Cancer Res 33:648–650, 1973.PubMedGoogle Scholar
  35. 35.
    Obata K, Ohno Y, Murase T, Aoki K, Tsugi K: Bladder cancer and HLA antigens. Nagoya J Med Sci 43:65–70, 1981.Google Scholar
  36. 36.
    Braf JF, Gazit E, Many M: HLA-A and B antigens in transitional cell carcinoma of the bladder. J Urol 122:465–466, 1979.PubMedGoogle Scholar
  37. 37.
    Arce S, Lopez R, Almaguer M, Ballester JM, Filgueiras E, Ustariz C, Perez S, Hernandez E: HL-A antigens and transitional-cell carcinoma of the bladder. Materia Medica Polona 10:98–100, 1978.PubMedGoogle Scholar
  38. 38.
    Ng A, Pellegrino MA, Imai K, Ferrone S: HLA-A, B antigens, la-like antigens, and tumor associated antigens on prostate carcinoma cell lines: serologic and immunochemical analysis with monoclonal antibodies. J Immunol 127:443–447, 1981.PubMedGoogle Scholar
  39. 39.
    Barry JM, Goldstein A, Hubbard M: Human leukocyte A and B antigens in patients with prostatic adenocarcinoma. J Urol 124:847–848, 1980.PubMedGoogle Scholar
  40. 40.
    Feingold N, Degos L, Feingold J: HLA in populations: An approach for genetical susceptibility to cancer. J Immunogen 6:29–35, 1979.CrossRefGoogle Scholar
  41. 41.
    Hogan B, Fellous M, Avner P, Jacob F: Isolation of a human teratoma cell line which expresses F9 antigen. Nature 270:515–518, 1977.PubMedCrossRefGoogle Scholar
  42. 42.
    Holden S, Bernard O, Artzt K, Whitmore WF Jr, Bennett D: Human and mouse embryonal carcinoma cells in culture share an embryonic antigen (F9). Nature 270:518–520, 1977.PubMedCrossRefGoogle Scholar
  43. 43.
    Avner P, Bono R, Berger R, Fellous M: Characterization of human teratoma cell lines for their in vitro developmental properties and expression of embryonic and major histocompatibility locus-associated antigens. J Immunogen 8:151–162, 1981.CrossRefGoogle Scholar
  44. 44.
    Andrews PW, Bronson DL, Wiles MV, Goodfellow PN: The expression of MHC antigens by human teratocarcinoma derived cell lines. Tissue Antigens 17:493–500, 1981.PubMedCrossRefGoogle Scholar
  45. 45.
    Carr BI, Bach FH: Possible association between HLA-AW24 and metastatic testicular germ cell tumors. Lancet ii:1346–1347, 1979.CrossRefGoogle Scholar
  46. 46.
    Majsky A, Abrahamova J, Korinkova P, Bek V: HLA system and testicular germinative tumors. Oncology 36:228–231, 1979.PubMedCrossRefGoogle Scholar
  47. 47.
    Lapes M, Iozzi L, Ziegenfus WD, Antoniades K, Vivacqua R: Familial testicular cancer in a father (bilateral seminoma-embryonal cell carcinoma) and son (teratocarcinoma). Cancer 39:2317–2320, 1977.PubMedCrossRefGoogle Scholar
  48. 1.
    Lilly F, Boyse EA, Old LJ: Genetic basis of susceptibility to viral leukaemogenesis. Lancet ii:1207–1209, 1964.CrossRefGoogle Scholar
  49. 2.
    Goyert S, Shively JE, Silver J: Biochemical characterization of a second family of human Ia molecules, HLA-DS, equivalent to murine I-A subregion molecules. J Exp Med 156:550–566, 1982.PubMedCrossRefGoogle Scholar
  50. 3.
    Zeevi A, Scheffel C, Anne K, Bass G, Marrari M, Duquesnoy RJ: Association of PLT specificity of alloreactive lymphocyte clones with HLA-DR, MB, and MT determinants. Immunogenetics 16:209–218, 1982.PubMedCrossRefGoogle Scholar
  51. 4.
    Shaw S, Pollack MS, Payne SM, Johnson AH: HLA linked B-cell antigens of a new segregant series defined by secondary allogeneic proliferative and cytotoxic responses. Hum Immunol 1:177–186, 1980.PubMedCrossRefGoogle Scholar
  52. 5.
    Pawelec G, Shaw S, Wernet P: Analysis of the HLA-linked SB gene system with cloned and uncloned alloreactive T-cell lines. Immunogenetics 15:187, 1982.PubMedGoogle Scholar
  53. 6.
    Shaw S, DeMars R, Schlossman SF, Smith PL, Lampson LA, Nadler LM: Serologic identification of the human secondary B cell antigens. Correlation between function, genetics and structure. J Exp Med 156:731–743, 1982.PubMedCrossRefGoogle Scholar
  54. 7.
    Shackelford DA, Lampson LA, Strominger JL: Separation of three class II antigens from a homozygous human B cell line. J Immunol 130:289, 1983.PubMedGoogle Scholar
  55. 8.
    Uhr JW, Capara JD, Vitteta ES et al.: Organization of the immune response genes. Science 206:292–297, 1979.PubMedCrossRefGoogle Scholar
  56. 9.
    Ryder LP, Andersen E, Svejgaard A (eds): HLA and Disease Registry: Third Report. Copenhagen: Munksgaard, 1979.Google Scholar
  57. 10.
    Tiwari JL, Terasaki PI: HLA-DR and disease associations. In: The Lymphocyte, Sell K, Miller WV (eds). New York: Alan R Liss, pp 151–163, 1981.Google Scholar
  58. 11.
    Betuel H, Gebuhrer L, Descos L et al.: Adult celiac disease associated with -HLA-DRw3 and -DRw7. Tissue Antigens 15:231–238, 1980.PubMedCrossRefGoogle Scholar
  59. 12.
    Duquesnoy R, Marrari M, Vieira J: Definition of MB and MT by 8th International Histocompatibility Workshop B cell alloantiserum clusters. In: Histocompatibility Testing 1980, Terasaki PI, (ed). Los Angeles: UCLA, pp 861–863, 1980.Google Scholar
  60. 13.
    Pollack MS, Safai B, Dupont B: HLA-DR5 and DR2 are susceptibility factors for acquired immunodeficiency syndrome with Kaposi’s sarcoma in different ethnic subpopulations. Disease Markers: 135–139, 1983.Google Scholar
  61. 14.
    Safai B, Myskowski PL, Dupont B, Pollack MS: Association of HLA-DR5 with mycosis fungoides. J Invest Dermatol 80: 395–397, 1983.PubMedCrossRefGoogle Scholar
  62. 15.
    Winchester R, Toguchi T, Szer I, Burmester G, Galbo PL, Cuttner J, Capra JD, Nunez-Roldan A: Association of susceptibility to certain hematopoietic malignancies with the presence of Ia allodeterminants distinct from the DR series. Utility of monoclonal antibody reagents. Immunol Rev 70:155–166, 1983.PubMedCrossRefGoogle Scholar
  63. 16.
    Myskowski PL, Pollack MS, Schor ES, Dupont B, Safai B: HLA associations in basal cell carcinoma. Clin Res 31:590A, 1983.Google Scholar
  64. 17.
    Baur MP, Danilovs JA: Reference tables of two and three locus haplotype frequencies for HLA-A,B,C,DR,Bf, and GLO. In: Histocompatibility Testing 1980, Terasaki PI (ed). Los Angeles: UCLA, pp 994–1210, 1980.Google Scholar
  65. 18.
    Hors J, Dausset J: HLA and susceptibility to Hodgkin’s disease. Immunol Rev 70:167–191, 1983.PubMedCrossRefGoogle Scholar
  66. 19.
    Batchelor JR, Morris PJ (eds): HLA and Disease. In: Histocompatibility Testing 1977, Nodmer WF, Batchelor JR, Bodmer JG, Festenstein H, Morris PJ (eds), pp 205–258, 1977.Google Scholar
  67. 20.
    Svejgaard A, Platz P, Ryder LP: Insulin-dependent diabetes mellitus. In: Histocompatibility Testing 1980, Terasaki PI (ed). Los Angeles: UCLA, pp 638–656, 1980.Google Scholar
  68. 21.
    Dawkins R: Myasthenia gravis. In: Histocompatibility Testing 1980, Terasaki PI (ed). Los Angeles: UCLA, pp 662–667, 1980.Google Scholar
  69. 22.
    Gladman DD, Keystone EC, Baron M, Lee P, Cane D, Mervert H: Increased frequency of HLA-DR5 in scleroderma. Arthritis Rhem 24:854–856, 1981.CrossRefGoogle Scholar
  70. 23.
    Suciu-Foca N, Godfrey M, Jacobs J, Khan R, Rohowsky C, Foca-Rodi A, Woodward K, Hardy M: Increased frequency of DRw5 in Pauci-articular JRA. In: Histocompatibility Testing 1980, Terasaki PI (ed). Los Angeles: UCLA, p 953, 1980.Google Scholar
  71. 24.
    Wakisaki A, Nakai Y, Kano T, Aizawa M, Moriuchi J, Itakura K: Complexity of DRw5 in Japanese. In: Histocompatibility Testing 1980, Terasaki PI (ed). Los Angeles: UCLA, p 806, 1980.Google Scholar
  72. 25.
    Curtoni ES, Borelli I, Cornaglia M, Olivetti E: Complexity of DRw5. In: Histocompatibility Testing 1980, Terasaki PI (ed). Los Angeles: UCLA, p 805, 1980.Google Scholar
  73. 26.
    Engelfreit C, de Lange G, Hilterman T, van den Berg-Loonen E: DR5. In: Histocompatibility Testing 1980, Terasaki PI (ed). Los Angeles: UCLA, pp 518–521, 1980.Google Scholar
  74. 27.
    Mizrachi Y, Orgad S, Jonash A, Avigad S, Yaron M, Gazit E: DRw5 heterogeneity in the Jewish population. In: Histocompatibility Testing 1980, Terasaki PI (ed). Los Angeles: UCLA, p 807, 1980.Google Scholar
  75. 28.
    DeWolf WC, Lange PH, Shepard R, Martin-Alosco S, Yunis EJ: Association of HLA and renal cell carcinoma. Human Immunol 1:41–44, 1981.CrossRefGoogle Scholar
  76. 29.
    Aiginger P, Schwarz HP, Kumits R, Kuhbock J, Schemper M, Mayr WR, Karrer K: HLA-A,B,C and DR antigens and testicular cancer: a prospective study. Proc Am Assoc Cancer Res (Abstracts), p 190, 1983.Google Scholar
  77. 30.
    Pollack MS, Vugrin D, Hennessy W, Herr HW, Dupont B, Whitmore WF: HLA antigens in patients with germ cell cancer of the testis. Cancer Res 42:2470–2473, 1982.PubMedGoogle Scholar
  78. 31.
    Terasaki PI, Perdue ST, Mickey MR: HLA frequencies in cancer. A second study. In: Genetics of Human Cancer, Mulvihill JJ, Miller RW, Fraumeni JF Jr (eds). New York: Raven Press, pp 321–328, 1977.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • Arthur I. Sagalowsky
  • Marilyn S. Pollack

There are no affiliations available

Personalised recommendations